40
Participants
Start Date
February 11, 2008
Primary Completion Date
October 25, 2011
Study Completion Date
April 24, 2026
paclitaxel albumin-stabilized nanoparticle formulation
100 mg/m2 3 weeks on 1 week off
pharmacological study
Cycle 1, week 1 at 0, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 24 and 48 hours
physiologic testing
Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
questionnaire administration
Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
study of socioeconomic and demographic variables
Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
cognitive assessment
Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
psychosocial assessment and care
Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
City of Hope Medical Group, Pasadena
City of Hope Medical Center, Duarte
National Cancer Institute (NCI)
NIH
City of Hope Medical Center
OTHER